Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Liabilities and Shareholders Equity: 2018-2021

  • Genmab A's Liabilities and Shareholders Equity rose 25.01% to $2,670 in Q2 2021 from the same period last year, while for Jun 2021 it was $4.0 billion, marking a year-over-year increase of 15.64%. This contributed to the annual value of $2.4 billion for FY2020, which is 55.39% up from last year.
  • Per Genmab A's latest filing, its Liabilities and Shareholders Equity stood at $2,670 for Q2 2021, which was down 100.00% from $2.4 billion recorded in Q4 2020.
  • In the past 5 years, Genmab A's Liabilities and Shareholders Equity ranged from a high of $2.4 billion in Q4 2020 and a low of $2,136 during Q2 2020.
  • Its 3-year average for Liabilities and Shareholders Equity is $987.6 million, with a median of $951.0 million in 2019.
  • In the last 5 years, Genmab A's Liabilities and Shareholders Equity surged by 66.88% in 2019 and then tumbled by 100.00% in 2020.
  • Quarterly analysis of 4 years shows Genmab A's Liabilities and Shareholders Equity stood at $935.5 million in 2018, then soared by 66.88% to $1.6 billion in 2019, then surged by 55.39% to $2.4 billion in 2020, then climbed by 25.01% to $2,670 in 2021.
  • Its Liabilities and Shareholders Equity stands at $2,670 for Q2 2021, versus $2.4 billion for Q4 2020 and $2,136 for Q2 2020.